Wang XY, Feng YG, Zhang HM, Ju LY, Bai HX, Gao GP, Zhang JH. Efficacy and safety of low-dose tricyclic antidepressants in patients with irritable bowel syndrome: a meta-analysis.
Shijie Huaren Xiaohua Zazhi 2011;
19:3458-3463. [DOI:
10.11569/wcjd.v19.i33.3458]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To systematically assess the efficacy and safety of low-dose tricyclic antidepressants (TCAs) for irritable bowel syndrome (IBS).
METHODS: PubMed, The Cochrane Central Register of Controlled Trials and Chinese Biomedical Literature Database, and CNKI were searched for double-blind, placebo-controlled trials investigating the efficacy of TCAs in the management of IBS. The Revman4.2 software provided by the Cochrane Collaboration was used for assessment.
RESULTS: Eight placebo-controlled, double-blind, randomized trials including 334 patients were involved in this analysis. TCAs used in these studies included amitriptyline, imipramine, desipramine, doxepin and trimipramine. Compared to placebo (40.76%), TCAs (72.43%) were associated with a higher rate of global symptom relief [40.76% vs 72.43%; RR = 1.79, 95%CI = (1.48, 2.17), P < 0.05]. There was a greater improvement in abdominal pain score [SMD = -1.68, 95%CI = (-3.13, -0.23), P < 0.05)] with TCAs than placebo. There was no significant difference in the incidence of serious adverse events between the TCA and placebo groups [RR = 1.34, 95%CI = (0.91, 1.96), P > 0.05].
CONCLUSION: Low-dose TCAs may be effective and safe in relief of the symptoms of IBS patients, especially in the improvement of abdominal pain score.
Collapse